{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:35:41Z","timestamp":1793043341967,"version":"4.5.0"},"reference-count":66,"publisher":"The Endocrine Society","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prolactinomas account for approximately half of the pituitary adenomas and predominantly affect women of reproductive age. Hyperprolactinemia commonly causes infertility by suppressing hypothalamic gonadotropin-releasing hormone secretion and impairing gonadal function. Because dopamine agonist therapy can rapidly restore fertility, clinicians caring for women with prolactinomas should be qualified to manage problems that may arise during pregnancy. Pregnancy is characterized by physiological enlargement of the anterior pituitary gland and progressive hyperprolactinemia, primarily driven by increased placental estrogen secretion. Therefore, the management of prolactinoma during preconception, pregnancy, and the postpartum period requires an individualized, multidisciplinary approach by an experienced team. The principal challenges are symptomatic tumor enlargement and, rarely, pituitary apoplexy. If clinically significant tumor growth occurs during pregnancy, dopamine agonist therapy can be safely restarted. Both bromocriptine and cabergoline may be used safely during gestation, but cabergoline is increasingly preferred because of its greater efficacy and better tolerability. In patients with pituitary apoplexy, management may include close observation, dopamine agonist therapy, glucocorticoid replacement when indicated, or transsphenoidal surgery, depending on the severity of clinical and neuroophthalmological findings. Breastfeeding can generally be permitted in women with prolactinomas; therefore, dopamine agonist therapy should be withheld during lactation unless treatment is clinically necessary. This review discusses the practical aspects of recognizing and managing prolactinoma-related problems before, during, and after pregnancy.<\/jats:p>","DOI":"10.1210\/clinem\/dgag408","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:41:08Z","timestamp":1790941268000},"source":"Crossref","is-referenced-by-count":0,"title":["Approach to the pregnant patient with prolactinoma"],"prefix":"10.1210","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3241-2352","authenticated-orcid":false,"given":"Zuleyha","family":"Karaca","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Erciyes University Medical School , Kayseri 38280 ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2861-4683","authenticated-orcid":false,"given":"Fahrettin","family":"Kelestimur","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Yeditepe University Medical School , \u0130stanbul 34718 ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"issue":"2","key":"2026102614502692900_dgag408-B1","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of prolactinomas: the old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"2026102614502692900_dgag408-B2","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.beem.2011.07.006","article-title":"Pregnancy and other pituitary disorders (including GH deficiency)","volume":"25","author":"Karaca","year":"2011","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"2026102614502692900_dgag408-B3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1530\/EJE-09-0923","article-title":"Pregnancy and pituitary disorders","volume":"162","author":"Karaca","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026102614502692900_dgag408-B4","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.92","article-title":"Sheehan syndrome","volume":"2","author":"Karaca","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"2026102614502692900_dgag408-B5","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.beem.2011.05.011","article-title":"Prolactinoma in pregnancy","volume":"25","author":"Molitch","year":"2011","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"2026102614502692900_dgag408-B6","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-21-0462","article-title":"ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy","volume":"185","author":"Luger","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2026102614502692900_dgag408-B7","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society International Consensus Statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"2026102614502692900_dgag408-B8","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2026.102081","article-title":"Fertility and pregnancy in patients with prolactinoma","volume":"40","author":"Stumpf","year":"2026","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"12","key":"2026102614502692900_dgag408-B9","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/jne.12223","article-title":"Prolactin regulation of kisspeptin neurones in the mouse brain and its role in the lactation-induced suppression of kisspeptin expression","volume":"26","author":"Brown","year":"2014","journal-title":"J Neuroendocrinol"},{"issue":"5978","key":"2026102614502692900_dgag408-B10","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/bmj.3.5978.274","article-title":"An abnormality of oestrogen feedback in amenorrhoea-galactorrhoea","volume":"3","author":"Glass","year":"1975","journal-title":"Br Med J"},{"issue":"6","key":"2026102614502692900_dgag408-B11","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1210\/jcem-54-6-1246","article-title":"Prolactin directly inhibits basal as well as gonadotropin-stimulated secretion of progesterone and 17 beta-estradiol in the human ovary","volume":"54","author":"Demura","year":"1982","journal-title":"J Clin Endocrinol Metab"},{"issue":"5807","key":"2026102614502692900_dgag408-B12","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/290600a0","article-title":"Prolactin inhibits oestrogen synthesis in the ovary","volume":"290","author":"Dorrington","year":"1981","journal-title":"Nature"},{"issue":"4","key":"2026102614502692900_dgag408-B13","first-page":"486","article-title":"Prolactin hypersecretion and short luteal phase defects","volume":"47","author":"Corenblum","year":"1976","journal-title":"Obstet Gynecol"},{"issue":"3","key":"2026102614502692900_dgag408-B14","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ecl.2024.05.004","article-title":"Prolactinomas: preconception and during pregnancy","volume":"53","author":"Zhang","year":"2024","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"8","key":"2026102614502692900_dgag408-B15","doi-asserted-by":"crossref","first-page":"e3515","DOI":"10.1210\/clinem\/dgac166","article-title":"Kisspeptin overcomes GnRH neuronal suppression secondary to hyperprolactinemia in humans","volume":"107","author":"Hoskova","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026102614502692900_dgag408-B16","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1210\/js.2017-00328","article-title":"Hypothalamic-pituitary-ovarian axis reactivation by kisspeptin-10 in hyperprolactinemic women with chronic amenorrhea","volume":"1","author":"Millar","year":"2017","journal-title":"J Endocr Soc"},{"issue":"2","key":"2026102614502692900_dgag408-B17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11102-026-01648-y","article-title":"Pregnancy and delivery after surgical remission in women with prolactinomas desiring pregnancy: refining surgical indications","volume":"29","author":"Amano","year":"2026","journal-title":"Pituitary"},{"issue":"3","key":"2026102614502692900_dgag408-B18","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ecl.2019.05.004","article-title":"Pituitary tumors in pregnancy","volume":"48","author":"Huang","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"2026102614502692900_dgag408-B19","doi-asserted-by":"crossref","first-page":"R205","DOI":"10.1530\/EJE-14-0848","article-title":"Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma","volume":"172","author":"Molitch","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026102614502692900_dgag408-B20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11102-019-01010-5","article-title":"Prolactinomas in pregnancy: considerations before conception and during pregnancy","volume":"23","author":"Glezer","year":"2020","journal-title":"Pituitary"},{"issue":"3","key":"2026102614502692900_dgag408-B21","doi-asserted-by":"crossref","DOI":"10.1002\/bdr2.2464","article-title":"Cabergoline use and pregnancy outcomes: a systematic review","volume":"117","author":"Otis","year":"2025","journal-title":"Birth Defects Res"},{"issue":"9","key":"2026102614502692900_dgag408-B22","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1210\/clinem\/dgad174","article-title":"Approach to the patient with prolactinoma","volume":"108","author":"Auriemma","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"14","key":"2026102614502692900_dgag408-B23","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","article-title":"A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group","volume":"331","author":"Webster","year":"1994","journal-title":"N Engl J Med"},{"issue":"6","key":"2026102614502692900_dgag408-B24","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1210\/jc.2009-2605","article-title":"Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas","volume":"95","author":"Ono","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026102614502692900_dgag408-B25","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1210\/clinem\/dgaf624","article-title":"Approach to the patient with dopamine-resistant microprolactinoma","volume":"111","author":"Glezer","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026102614502692900_dgag408-B26","first-page":"452","article-title":"Women with prolactinoma--effect of pregnancy and lactation on serum prolactin and on tumour growth","volume":"111","author":"Holmgren","year":"1986","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"2","key":"2026102614502692900_dgag408-B27","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11102-019-01008-z","article-title":"A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas","volume":"23","author":"Sant\u2019 Anna","year":"2020","journal-title":"Pituitary"},{"issue":"6","key":"2026102614502692900_dgag408-B28","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1055\/a-1468-4608","article-title":"Outcomes of patients with macroprolactinoma desiring pregnancy: follow-up to 23 years from a single center","volume":"53","author":"Tanrikulu","year":"2021","journal-title":"Horm Metab Res"},{"issue":"4","key":"2026102614502692900_dgag408-B29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.23736\/S0391-1977.17.02792-4","article-title":"Prolactinomas: how to handle prior to and during pregnancy?","volume":"43","author":"Glezer","year":"2018","journal-title":"Minerva Endocrinol"},{"issue":"3","key":"2026102614502692900_dgag408-B30","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1210\/clinem\/dgz144","article-title":"Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis","volume":"105","author":"Zamanipoor Najafabadi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026102614502692900_dgag408-B31","first-page":"21557","article-title":"Effect of transsphenoidal surgery and standard care on fertility related indicators of patients with prolactinomas during child-bearing period","volume":"8","author":"Yan","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"2026102614502692900_dgag408-B32","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9930059","article-title":"Surgery and medical treatment in microprolactinoma: a systematic review and meta-analysis","volume":"2021","author":"Lu","year":"2021","journal-title":"Int J Endocrinol"},{"issue":"12","key":"2026102614502692900_dgag408-B33","doi-asserted-by":"crossref","first-page":"e4242","DOI":"10.1210\/clinem\/dgaf434","article-title":"Debate: surgery as initial therapy for microprolactinoma","volume":"110","author":"Molitch","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026102614502692900_dgag408-B34","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1210\/jc.2016-2008","article-title":"Dopamine agonists can reduce cystic prolactinomas","volume":"101","author":"Faje","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026102614502692900_dgag408-B35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5152\/erp.2024.23291","article-title":"Pregnancy and pituitary diseases","volume":"28","author":"Urhan","year":"2024","journal-title":"Endocrinol Res Pract"},{"issue":"4","key":"2026102614502692900_dgag408-B36","doi-asserted-by":"crossref","first-page":"e1241","DOI":"10.1210\/clinem\/dgae821","article-title":"Disease activity and maternal-fetal outcomes in pregnant women with prolactinoma: a systematic review and meta-analysis","volume":"110","author":"Bandeira","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026102614502692900_dgag408-B37","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1097\/AOG.0000000000002355","article-title":"Committee opinion No. 723: guidelines for diagnostic imaging during pregnancy and lactation","volume":"130","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"2 Pt 1","key":"2026102614502692900_dgag408-B38","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/AOG.0b013e318180a505","article-title":"Guidelines for computed tomography and magnetic resonance imaging use during pregnancy and lactation","volume":"112","author":"Chen","year":"2008","journal-title":"Obstet Gynecol"},{"issue":"9","key":"2026102614502692900_dgag408-B39","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jama.2016.12126","article-title":"Association between MRI exposure during pregnancy and fetal and childhood outcomes","volume":"316","author":"Ray","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"2026102614502692900_dgag408-B40","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/jmri.24011","article-title":"ACR guidance document on MR safe practices: 2013","volume":"37","author":"Kanal","year":"2013","journal-title":"J Magn Reson Imaging"},{"issue":"4","key":"2026102614502692900_dgag408-B41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/1753495X15598917","article-title":"Pituitary apoplexy in pregnancy: a case series and literature review","volume":"8","author":"Grand'Maison","year":"2015","journal-title":"Obstet Med"},{"issue":"1","key":"2026102614502692900_dgag408-B42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2265.2010.03913.x","article-title":"UK guidelines for the management of pituitary apoplexy","volume":"74","author":"Rajasekaran","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2026102614502692900_dgag408-B43","article-title":"Microprolactinoma growth during pregnancy with pituitary tumor apoplexy: case report and review of the literature","volume":"2025","author":"Introini","year":"2025","journal-title":"Case Rep Endocrinol"},{"issue":"1","key":"2026102614502692900_dgag408-B44","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1530\/EJE-21-0145","article-title":"Apoplexy of microprolactinomas during pregnancy: report of five cases and review of the literature","volume":"185","author":"Kuhn","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026102614502692900_dgag408-B45","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/09513590.2019.1650339","article-title":"A case of atypical macroprolactinoma presenting with pituitary apoplexy during pregnancy and review of the literature","volume":"36","author":"Oguz","year":"2020","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"2026102614502692900_dgag408-B46","doi-asserted-by":"crossref","first-page":"R49","DOI":"10.1093\/ejendo\/lvag034","article-title":"Management of endocrine disease: update on the management of pituitary apoplexy","volume":"194","author":"Biagetti","year":"2026","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026102614502692900_dgag408-B47","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0890-6238(96)00134-7","article-title":"Reproductive toxicity of cabergoline in mice, rats, and rabbits","volume":"10","author":"Beltrame","year":"1996","journal-title":"Reprod Toxicol"},{"issue":"1","key":"2026102614502692900_dgag408-B48","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40618-017-0709-8","article-title":"How does pregnancy affect the patients with pituitary adenomas: a study on 113 pregnancies from Turkey","volume":"41","author":"Karaca","year":"2018","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2026102614502692900_dgag408-B49","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11102-024-01384-1","article-title":"Prolactin-secreting tumors, dopamine agonists and pregnancy: a longitudinal experience of a tertiary neuroendocrine center","volume":"27","author":"Prencipe","year":"2024","journal-title":"Pituitary"},{"issue":"1","key":"2026102614502692900_dgag408-B50","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s12020-014-0334-7","article-title":"Prolactinomas, cabergoline, and pregnancy","volume":"47","author":"Glezer","year":"2014","journal-title":"Endocrine"},{"issue":"1","key":"2026102614502692900_dgag408-B51","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/AOG.0000000000001747","article-title":"Macroprolactinomas and nonfunctioning pituitary adenomas and pregnancy outcomes","volume":"129","author":"Lambert","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"4","key":"2026102614502692900_dgag408-B52","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/09513590.2016.1254177","article-title":"Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy","volume":"33","author":"Rastogi","year":"2017","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"2026102614502692900_dgag408-B53","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00404-014-3210-z","article-title":"Pregnancy outcome in women exposed to dopamine agonists during pregnancy: a pharmacoepidemiology study in EFEMERIS database","volume":"290","author":"Hurault-Delarue","year":"2014","journal-title":"Arch Gynecol Obstet"},{"issue":"5","key":"2026102614502692900_dgag408-B54","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/cen.15304","article-title":"Safety of cabergoline for prolactinoma in pregnancy: a systematic review and meta-analysis","volume":"103","author":"Chakraborty","year":"2025","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"2026102614502692900_dgag408-B55","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1055\/s-0043-112861","article-title":"Pregnancy and tumor outcomes in women with prolactinoma","volume":"125","author":"Araujo","year":"2017","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"8","key":"2026102614502692900_dgag408-B56","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/0002-9378(83)90968-7","article-title":"Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas","volume":"146","author":"Konopka","year":"1983","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"2026102614502692900_dgag408-B57","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11102-005-5083-4","article-title":"Prolactinomas and pregnancy","volume":"8","author":"Bronstein","year":"2005","journal-title":"Pituitary"},{"issue":"17","key":"2026102614502692900_dgag408-B58","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/BF01727477","article-title":"Bromocriptine in pregnancy: safety aspects","volume":"65","author":"Krupp","year":"1987","journal-title":"Klin Wochenschr"},{"issue":"3","key":"2026102614502692900_dgag408-B59","first-page":"239","article-title":"Follow-up of children born of bromocriptine-treated mothers","volume":"22","author":"Raymond","year":"1985","journal-title":"Horm Res"},{"key":"2026102614502692900_dgag408-B60","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2026.1806870","article-title":"Impact of bromocriptine withdrawal timing on pregnancy outcomes in patients with pituitary prolactin-secreting microadenomas: a real-world retrospective study of 188 pregnancies in China","volume":"17","author":"Lan","year":"2026","journal-title":"Front Pharmacol"},{"issue":"2","key":"2026102614502692900_dgag408-B61","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2265.2010.03808.x","article-title":"Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women","volume":"73","author":"Lebbe","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2026102614502692900_dgag408-B62","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11102-010-0243-6","article-title":"Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature","volume":"13","author":"Stalldecker","year":"2010","journal-title":"Pituitary"},{"issue":"4","key":"2026102614502692900_dgag408-B63","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2165\/00002018-199614040-00003","article-title":"A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation","volume":"14","author":"Webster","year":"1996","journal-title":"Drug Saf"},{"issue":"1","key":"2026102614502692900_dgag408-B64","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0002-9378(72)90446-2","article-title":"Studies of prolactin secretion in human pregnancy","volume":"113","author":"Tyson","year":"1972","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"2026102614502692900_dgag408-B65","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12020-017-1438-7","article-title":"Prolactinoma through the female life cycle","volume":"59","author":"Cocks Eschler","year":"2018","journal-title":"Endocrine"},{"issue":"3","key":"2026102614502692900_dgag408-B66","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1210\/jcem-38-3-413","article-title":"Prolactin release during nursing and breast stimulation in postpartum and nonpostpartum subjects","volume":"38","author":"Noel","year":"1974","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag408\/71575925\/dgag408.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag408\/71575925\/dgag408.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:50:40Z","timestamp":1793040640000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article\/doi\/10.1210\/clinem\/dgag408\/8860182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":66,"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag408","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"article-number":"dgag408"}}